# Immunogenicity and Safety of Different Doses of Fluzone® Influenza

> **NCT00253734** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 217 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Fluzone® (IM)
- **BIOLOGICAL:** Fluzone®

## Key facts

- **NCT ID:** NCT00253734
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2006-10
- **Final completion:** 2006-11
- **Target enrollment:** 217 (ACTUAL)
- **Last updated:** 2013-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00253734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00253734, "Immunogenicity and Safety of Different Doses of Fluzone® Influenza". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00253734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*